> top > docs > PMC:1283364 > spans > 2831-3231 > annotations

PMC:1283364 / 2831-3231 JSONTXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

Id Subject Object Predicate Lexical cue
T818 94-100 VB denotes arrest
T821 1-3 IN denotes of
T822 4-10 NNS denotes events
T823 11-18 VBG denotes leading
T824 19-21 IN denotes to
T825 22-29 NN denotes disease
T826 29-31 , denotes ,
T827 31-35 RB denotes then
T828 36-47 JJ denotes therapeutic
T829 48-58 NNS denotes strategies
T830 59-63 WDT denotes that
T831 64-69 VBP denotes lower
T832 70-72 NN denotes Aβ
T833 73-79 NNS denotes levels
T834 80-86 MD denotes should
T835 87-93 CC denotes either
T836 101-103 CC denotes or
T837 104-111 VB denotes reverse
T838 112-115 DT denotes the
T839 116-127 NN denotes progression
T840 128-132 IN denotes from
T841 133-140 NN denotes peptide
T842 141-143 IN denotes to
T843 144-152 NN denotes dementia
T844 152-153 . denotes .
T845 153-365 sentence denotes Early evidence from clinical trials of antibody-mediated clearance, one of the first Aβ-lowering approaches tested in humans, suggested that treatments designed to reduce amyloid burden may indeed be beneficial.
T846 154-159 JJ denotes Early
T847 160-168 NN denotes evidence
T848 280-289 VBD denotes suggested
T849 169-173 IN denotes from
T850 174-182 JJ denotes clinical
T851 183-189 NNS denotes trials
T852 190-192 IN denotes of
T853 193-201 NN denotes antibody
T854 202-210 VBN denotes mediated
T855 201-202 HYPH denotes -
T856 211-220 NN denotes clearance
T857 220-222 , denotes ,
T858 222-225 CD denotes one
T859 226-228 IN denotes of
T860 229-232 DT denotes the
T861 251-261 NNS denotes approaches
T862 233-238 JJ denotes first
T863 239-241 NN denotes Aβ
T864 242-250 VBG denotes lowering
T865 241-242 HYPH denotes -
T866 262-268 VBN denotes tested
T867 269-271 IN denotes in
T868 272-278 NNS denotes humans
T869 278-280 , denotes ,
T870 290-294 IN denotes that
T871 351-353 VB denotes be
T872 295-305 NNS denotes treatments
T873 306-314 VBN denotes designed
T874 315-317 TO denotes to
T875 318-324 VB denotes reduce
T876 325-332 NN denotes amyloid
T877 333-339 NN denotes burden
T878 340-343 MD denotes may
T879 344-350 RB denotes indeed
T880 354-364 JJ denotes beneficial
T881 364-365 . denotes .
T883 366-374 IN denotes Although
T884 391-397 VBN denotes halted
T885 375-378 DT denotes the
T886 379-385 NNS denotes trials
T887 386-390 VBD denotes were
R434 T822 T821 pobj events,of
R435 T823 T822 acl leading,events
R436 T824 T823 prep to,leading
R437 T825 T824 pobj disease,to
R438 T826 T818 punct ", ",arrest
R439 T827 T818 advmod then,arrest
R440 T828 T829 amod therapeutic,strategies
R441 T829 T818 nsubj strategies,arrest
R442 T830 T831 dep that,lower
R443 T831 T829 relcl lower,strategies
R444 T832 T833 compound Aβ,levels
R445 T833 T831 dobj levels,lower
R446 T834 T818 aux should,arrest
R447 T835 T818 preconj either,arrest
R448 T836 T818 cc or,arrest
R449 T837 T818 conj reverse,arrest
R450 T838 T839 det the,progression
R451 T839 T837 dobj progression,reverse
R452 T840 T839 prep from,progression
R453 T841 T840 pobj peptide,from
R454 T842 T840 prep to,from
R455 T843 T842 pobj dementia,to
R456 T844 T818 punct .,arrest
R457 T846 T847 amod Early,evidence
R458 T847 T848 nsubj evidence,suggested
R459 T849 T847 prep from,evidence
R460 T850 T851 amod clinical,trials
R461 T851 T849 pobj trials,from
R462 T852 T851 prep of,trials
R463 T853 T854 npadvmod antibody,mediated
R464 T854 T856 amod mediated,clearance
R465 T855 T854 punct -,mediated
R466 T856 T852 pobj clearance,of
R467 T857 T856 punct ", ",clearance
R468 T858 T856 appos one,clearance
R469 T859 T858 prep of,one
R470 T860 T861 det the,approaches
R472 T862 T861 amod first,approaches
R473 T863 T864 npadvmod Aβ,lowering
R474 T864 T861 amod lowering,approaches
R475 T865 T864 punct -,lowering
R476 T866 T861 acl tested,approaches
R477 T867 T866 prep in,tested
R478 T868 T867 pobj humans,in
R479 T869 T848 punct ", ",suggested
R480 T870 T871 mark that,be
R481 T871 T848 ccomp be,suggested
R482 T872 T871 nsubj treatments,be
R483 T873 T872 acl designed,treatments
R484 T874 T875 aux to,reduce
R485 T875 T873 advcl reduce,designed
R486 T876 T877 compound amyloid,burden
R487 T877 T875 dobj burden,reduce
R488 T878 T871 aux may,be
R489 T879 T871 advmod indeed,be
R490 T880 T871 acomp beneficial,be
R491 T881 T848 punct .,suggested
R492 T883 T884 mark Although,halted
R494 T885 T886 det the,trials
R495 T886 T884 nsubjpass trials,halted
R496 T887 T884 auxpass were,halted
R471 T861 T859 pobj approaches,of

craft-ca-core-ex-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T632 70-72 CHEBI_PR_EXT:amyloid_beta denotes Aβ
T633 133-140 CHEBI_SO_EXT:peptide_or_peptide_region denotes peptide
T634 193-201 GO:0042571 denotes antibody
T635 239-241 CHEBI_PR_EXT:amyloid_beta denotes Aβ
T636 272-278 NCBITaxon:9606 denotes humans
T637 325-332 CHEBI:60425 denotes amyloid

craft-ca-core-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T559 193-201 GO:0042571 denotes antibody
T560 272-278 NCBITaxon:9606 denotes humans
T561 325-332 CHEBI:60425 denotes amyloid